November has been a promising month for CytoSorbents Corp. (NASDAQ: CTSO), a critical care immunotherapy company. The New Jersey-based company, specializing in blood purification to control deadly inflammation in critically ill and cardiac surgery patients, reported its financial results for the third quarter ended September 30, 2016.
CTSO reported that product sales for the third quarter of this year were up to $2.14 million, a new record, marking the sixth quarter in a row to show substantial growth with sales up by 100% from 2015’s $1.07 million. The jump was attributed to increases in both direct sales and sales through distributors.
Total revenue for the third quarter of 2016, including product sales and grant revenue, came in at $2.4 million, marking an overall gross margin of $1.4 million compared to $0.7 million in the third quarter of 2015. In addition, product gross margins for the third quarter of 2016 were approximately 5% higher than in the same quarter of 2015.
As a result, Aegis Capital Corp. upgraded its CytoSorbents estimates, offering the company a ‘Buy’ rating with a target price of $20. The report states: “CTSO reported revenues of $2.41 million versus consensus of $2.21 million and our $2.25 million estimate.” The report also highlighted that Aegis expects further acceleration through 2017.
Highlights from the report include the growth of CytoSorb sales of 13,000 units, the fact that REFRESH 1 met its safety endpoint, and that CytoSorbents has $6.4 million in cash with $5 million available from its credit facility with Bridge Bank. As a result, the company expects to have enough funding for its operations through the second half of 2017.
CytoSorbents’ Q3 2016 sales report is not the only aspect of the company’s recent success. In November of this year, CTSO announced the addition of Belgium and Luxembourg to its direct sales directories, expanding its distribution to include 42 countries around the world. These new additions will allow CytoSorbents to target these focused markets with its own direct sales force.
For more information, visit the company’s website at www.cytosorbents.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment